JPH0533206B2 - - Google Patents

Info

Publication number
JPH0533206B2
JPH0533206B2 JP59098978A JP9897884A JPH0533206B2 JP H0533206 B2 JPH0533206 B2 JP H0533206B2 JP 59098978 A JP59098978 A JP 59098978A JP 9897884 A JP9897884 A JP 9897884A JP H0533206 B2 JPH0533206 B2 JP H0533206B2
Authority
JP
Japan
Prior art keywords
fraction
culture
medium
solution
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59098978A
Other languages
Japanese (ja)
Other versions
JPS60243019A (en
Inventor
Naochika Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Kasei Corp
Original Assignee
Mitsubishi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Kasei Corp filed Critical Mitsubishi Kasei Corp
Priority to JP59098978A priority Critical patent/JPS60243019A/en
Publication of JPS60243019A publication Critical patent/JPS60243019A/en
Publication of JPH0533206B2 publication Critical patent/JPH0533206B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は、肝細胞増殖因子に関する。 (従来の技術) 本発明者は、先に肝細胞の増殖因子を見出した
(日本組織培養学会第52回研究会で発表)が、さ
らに比活性を向上させた増殖因子を得るべく種々
検討を行ない、本発明に到達した。 (発明の要旨) すなわち、本発明の要旨は、温血動物の腸粘膜
のホモジネートより分画され、分子量が約2万で
ある肝細胞増殖因子にある。 (発明の構成) 以下、本発明を詳細に説明する。 まず、本発明における温血動物としては、ラツ
ト、マウス、ニワトリ、ヤギ、ウシ、ウサギ、ブ
タ、ウマ等が挙げられる。 これらの動物の腸粘膜の種類としては、小腸、
盲腸、十二指腸、空腸、回腸、大腸が挙げられる
が、通常、ウシ、ブタ、ニワトリ等の小腸、盲腸
が好適に使用される。 本発明に係る増殖因子は、たとえば、次のよう
な方法によつて得られる。 まず、上記動物の腸粘膜を採取する。採取は、
通常、擦過法により行い、腸上皮粘膜組織を得
る。これをカルシウム、好ましくはさらにマグネ
シウムを実質的に含有しない塩類溶液で処理して
ホモジネートを得る。これらの工程は通常0〜2
℃程度の温度で行なわれる。 上記塩類溶液としては、たとえばタイロード溶
液(Tyrode′s solution)(以下、「CMF」とい
う)が使用される。この溶液の組成は次のとおり
である。 Nacl 8.00 Na2HPO4 1.15 Kcl 0.20 KH2PO4 0.20 (g/l) 次いでホモジネートから、遠心分離等により上
清を得る。遠心分離によるときは、通常8000〜
12000×gで数分以上で行なわれる。得られた上
清は加熱され、変性した高分子タンパクは沈殿除
去される。加熱は60〜100℃程度で1分以上行な
われる。次いで上清を上記塩類溶液で透析処理
し、低分子量成分が除去される。 次いで、得られた画分(あるいは、上記加熱お
よび/または透析を行なわない遠心分離画分でも
よい)を“セフアデツクス”G−75、100または
200等によるゲルろ過に付し、得られる3つのピ
ークのうちの第1のピークを有する画分を分画す
る。 ついで、DEAEセルロースを用いて、イオン交
換クロマトグラフイー処理すると、6〜7の画分
に分画される。2番目の画分が目的とする増殖因
子である。 (発明の作用効果) 本発明の増殖因子は、次のような性質を有す
る。 a ConA(コンカナバリンA)−セフアロースク
ロマトグラフイーにより溶出される。すなわ
ち、多糖類または糖タンパク質の性状を示さな
い。 b SDSポリアクリルアミドゲルによる電気泳動
図は、分子量約2万にひとつのバンドを有す
る。 c 動物による種特異性を示さない。 d 良好な熱安定性を有する。 e 肝細胞の増殖促進作用を有し、かつ、他の組
織細胞の培養においてもウシ由来の胎児血清、
準胎児血清または子牛血清と同様の培養効果を
示す。 (発明の効果) 以上のように、本発明に係る肝細胞増殖因子
は、肝機能促進剤等としての用途が期待され、ま
た、無血清培地への培養促進剤としても有用であ
る。 (実施例) 以下、実施例により本発明をさらに詳細に説明
するが、本発明は、その要旨を超えない限り、以
下の実施例に限定されない。 実施例 1 (実験1) 加熱、透析したラツト小腸粘膜抽出
物のゲル過法による分画 1 実験動物と飼育条件 ゲル過にはスプレイグ ドーリイSprague−
Dawle系(以後「SD系」という)の生後2〜3
ケ月齢、体重200〜300gの雄から得た試料を使用
した。ラツトは飼料、飲料水ともに自由摂取と
し、飼料としては固型飼料(日本配合飼料K.K
製)を給与し、23℃前後に保温された環境下で飼
育した。 2 小腸粘膜抽出物の調製 ラツトを軽くエーテルで麻酔し、頸静脈を切
断、放血し、開腹後、全小腸を摘出し、内容物を
除去した後、眼科用ハサミで縦に切開し、CMF
−PBS液(ダルベコDulbeccoのリン酸緩衝塩類
溶液)で洗い、粘膜をピンセツトにより擦過採取
し、約2倍容のCMF−PBS液でホモジネート後、
12000×g、30分間遠心分離した上清を小腸粘膜
抽出物とした。 3 小腸粘膜抽出物の加熱、透析法 上述の小腸粘膜抽出物を100℃、2分間加熱後、
12000×g、20分間遠心分離し、上清を約30倍容
のCMF−PBS液で24時間透析した。 4 ゲル過法による分画 加熱、透析した小腸粘膜抽出物をコロジオンバ
ツグにより約5mlに濃縮し、分画用試料とした。 ゲル過に使用したゲルは“セフアデツクス
Sephadex G−75(フアルマシア フアイン ケ
ミカルPharmacia Fine Chemicals製)を用い
た。カラムは内径1.2cm、ゲル高120cmとした。
0.1MNacl・20mM Tris−HCl緩衝液(PH7.5)
によりゲルを洗い、試料を2mlほど添加し、同一
の緩衝液で下降法にて2ml/hrの流速で溶出し
た。 溶出された緩衝液をフラクシヨンコレクターに
よつて2ml分取し、280nmの吸光度を計測するこ
とにより溶出曲線を得た(図−1)。これにより
3つの画分を得たので次の実験−2の試料とし
た。 (実験2) 成熟ラツト肝細胞培養による肝細胞
増殖活性因子の検索 1 培養に用いた動物は8週齢、体重約150g
のSD系雄ラツトを用い、飼育は実験−1と
同様の条件で行なつた。なお、肝細胞の分離
操作及び培養は全て無菌条件で行なうため、
滅菌には特に注意を払つた。 2 成熟ラツト肝細胞分離法 肝細胞の分離はすべて次のような方法で行なつ
た。 ラツトに0.2mlのネンブタールを腹腔内に注射
して麻酔する。次に腹部を剃毛し、10%塩化ベン
ザルコニウム液で身体全体を消毒する(以後肝細
胞分離操作は振とうと遠心分離以外は全て無菌箱
中で行ない無菌的に操作する。)。 ラツトを手術用固定台に仰臥位に固定し、手術
用ハサミで腹部の皮膚、腹筋の順に開腹する。
CMF−PBS液をしみ込ませた脱脂綿で腸を術者
の右側にかきよけ門脈を十分露出させる。門脈に
縫合糸のループをかけ、眼科用ハサミの先端を使
つて門脈に切れ目を入れる。切開部にあらかじめ
設置しておいた灌流装置に前灌流緩衝液を流しな
がら溢れ出る血液をめがけてカニユーレを挿入
し、すばやく縫合糸で結紮する。同時に肝臓下の
下大静脈を切断し洗浄液を流出させる。そのまま
30ml/hrの流速で前灌流緩衝液を約200ml流した
後、ポンプを止める。灌流液をCMF−PBS液に
変え、同一の流速で約100ml流し洗浄した後、ポ
ンプを止め、灌流液をコラゲナーゼ溶液に変え、
同一の流速で約30ml流す。コラゲナーゼが肝臓全
体に浸透したところでポンプを止め、全肝臓を慎
重に摘出し、120mmガラスシヤーレに移す。約20
mlのコラゲナーゼ溶液を加え、カミソリの刃を鉗
子で交叉させ肝臓を2mm角の大きさに細切する。
細切した組織をコラゲナーゼ溶液ごと100ml溶三
角コルベンに移し、ブチル栓にて密栓し、37℃の
恒温振とう機で1分間に100振とうの割合で15分
間振とうする。振とう後、未消化の組織を細胞
過器によつて取り除き、上から約10mlのCMF−
PBS液で未消化の組織を洗い、全ての液を30
ml容の遠沈管に集め、密栓後50×g、1分間遠心
分離する。上清を捨て、新たに20mlのCMF−
PBS液を加えて洗浄し、ゆるやかにピペツテイ
ングし密栓後、遠沈管を氷冷し、50×g、1分管
遠心分離し上清を捨てる。再度CMF−PBS液を
加え懸濁し、2重ナイロン布の小片で過し、
液を新しい遠沈管に集めて密栓後、氷冷し、50×
g、1分間遠心分離する。上清を捨てた後、
CMF−PBS液による洗浄を2回繰り返すことに
より、肝実質細胞より比重の軽い非実質細胞が取
り除かれ、肝実質細胞が分離される。 3 前培養と前培養培地 酵素などにより損傷を受けた肝細胞は本来の肝
機能を失つているため、それを回腹させるため、
前培養を行なつた。 低速遠心法で精製した肝実質細胞を5%ラツト
血清(56℃、30分間の加熱で補体を無毒化したも
の)と10-6Mのデキサメサゾンを含む、ウイリア
ムのE培地(WE培地)に懸濁し、滅菌済のプラ
ステイクシヤーレ(35×10mm)に1.5mlの割合で
播く。培養液にはペニシリン(100U/ml)、スト
レプトマイシン(100ug/ml)、アンホテリシン
B(0.25μg/ml)などが添加してある。培養は5
%CO2−95%空気を気相として、37℃のCO2イン
キユベーター中で24時間行なう。24時間後には多
くの肝細胞がシヤーレ底面に接着している。 4 培養方法 前培養培地で24時間培養した後、目的の培地に
交換した。 培地には、前述のWE培地を基本培地とし、対
照区(control)として10%ラツト血清添加培地、
実験区として実験−1で得た画分1(0.02mg蛋
白/ml)、画分2(0.02mg蛋白/ml)、画分3(0.01
mg蛋白/ml)をそれぞれ10%添加した。 なお、画分1(tube No.33〜52)、画分2(tube
No.60〜85)、画分3(tube No.94〜120)、はそれ
ぞれコロジオンバツグにより適当量(5ml前後)
に濃縮し、30倍容のCMF−PBS液で24時間透析
し、ローリーLowly法で蛋白質濃度を測定した。 培地の交換は48時間毎に行なつた。 5 細胞数の測定日と測定法 前培養終了時を0日目として1日目、3日目、
6日目、9日目の細胞数を測定した。 測定法は、シヤーレを取り出し、培地を取り除
きトリプシン−EDTA混液(0.1%トリプシン、
0.02%EDTA−CMF−PBS液)で37℃、15分間
インキユベートし、細胞がシヤーレに残らなくな
るまで繰り返しはがした。その細胞浮遊液を500
×g、15分間遠心分離し、細胞を集めそれを既知
量のCMF−PBS液に懸濁し、トリパンブル−で
染色後、核の染まらないものを生細胞としてヘマ
トメーターにより算定した。なお、各実験区毎に
3個のシヤーレを測定しその平均値を細胞数とし
た。 6 実験結果 灌流法と低速遠心処理によつて得られた肝細胞
では、80%前後の生細胞が得られ、血球、非実質
細胞の混入もほとんどなかつた。 培養後の細胞数の変化および形態的変化をみた
ところ、培地に画分1を添加したものは顕著な増
殖が見られた。画分2及び3も3日目までは増殖
の傾向が見られたが6日目、9日目と日数が経つ
につれ細胞数が減つてゆき、画分3は6日目以後
は培養不能となつた。対照区の10%ラツト血清添
加培地では増殖が見られず6日目で培養不能とな
つた。 本実験により肝細胞増殖活性を持つ因子が画分
1にあることがわかり、少なくとも9日以上増殖
を維持することが明らかにされた。(なお、画分
2及び3の一時的な増殖は画分1の分画が画分2
及び3に少量混入したことによるものであつた。) (実験3) イオン交換セルロースカラムクロマ
トグラフイーによる分画 カラムに使用したセルロースイオン交換体は
DE−52(DEAEセルロース:ワツトマン
Wattman製)を用いた。カラムは内径3cm、高
さ30cmを使用し、実験−1と同様に緩衝液にて、
セルロースイオン交換体を平衡化して使用した。 上記実験−1で得た画分1をコロジオンバツグ
により約5mlに濃縮し分画用試料とした。 試料をカラムに5ml添加した後、0.1M、
0.2M、0.3M、0.4M、0.6M、0.8MのNaclにより
イオン強度を段階的に高め、吸着された物質を溶
出した。なお、1種類の緩衝液はそれせぞれ流す
量を250mlとし、10ml/hrの流速にて溶出し、溶
出された緩衝液をフラクシヨンコレクターによつ
て、5ml分取し280nmの吸光度を測定し、溶出曲
線を得た(図−2)。 これにより6つの画分を得たので、次の実験−
4の試料とした。 (実験4) 成熟ラツト肝細胞培養による肝細胞
増殖活性因子の検索 上記実験−2と同様の方法によつた。 なお、培養方法は、実験−2と同様に、前培養
を24時間行なつた後、実験区とし、画分1(0.02
mg蛋白/ml;tube No.10〜25)、画分2(0.02mg蛋
白/ml;tube No.66〜73)、画分3(0.02mg蛋白/
ml;tube No.130〜150)、画分4(0.002mg蛋白/
ml;tube No.157〜168)、画分5(0.002mg蛋白/
ml;tube No.169〜187)、画分6(0.002mg蛋白/
ml;tube No.196〜202)を基本培地に10%添加し
て行ない、細胞数の測定は、1日目と3日目とに
行なつた。 各画分の物性は分子量の測定とPAS染色によ
る糖の存在を調べ、細胞増殖活性を有する区分に
ついては、ポリアクリルアミド電気泳動法によつ
て蛋白組成を調べた。なお、分子量は、SDSポリ
アクリルアミド電気泳動法によつて測定した。 (実験結果) 培養後の細胞数の変化を表−1に示す。 すなわち、画分2を添加した培地のみが増殖を
示した。 分子量の測定では、SDSポリアクリルアミドに
よる測定において蛋白質の染色反応(クーマシー
ブリリアントブルー染色)が画分3,4,5及び
6に出ないことが明らかにされた。 ポリアクリルアミド電気泳動法による分画は、
細胞増殖活性の見られた画分2(すなわち、目的
とする増殖因子)について行なつた。その結果3
つのバンド(分子量約2万)が、アミドブラツク
染色により検出された。 【表】
DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to hepatocyte growth factors. (Prior art) The present inventor previously discovered a growth factor for hepatocytes (presented at the 52nd research meeting of the Japanese Society of Tissue Culture), but conducted various studies in order to obtain a growth factor with further improved specific activity. Through these efforts, the present invention was achieved. (Summary of the Invention) That is, the gist of the present invention is a hepatocyte growth factor that is fractionated from a homogenate of intestinal mucosa of a warm-blooded animal and has a molecular weight of about 20,000. (Structure of the Invention) The present invention will be described in detail below. First, warm-blooded animals in the present invention include rats, mice, chickens, goats, cows, rabbits, pigs, horses, and the like. The types of intestinal mucosa in these animals include small intestine,
Examples include the cecum, duodenum, jejunum, ileum, and large intestine, but usually the small intestine and cecum of cows, pigs, chickens, etc. are preferably used. The growth factor according to the present invention can be obtained, for example, by the following method. First, the intestinal mucosa of the above animal is collected. The collection is
It is usually performed by a scraping method to obtain intestinal epithelial mucosal tissue. This is treated with a saline solution substantially free of calcium and preferably further magnesium to obtain a homogenate. These steps are usually 0-2
It is carried out at a temperature of about ℃. As the above-mentioned salt solution, Tyrode's solution (hereinafter referred to as "CMF"), for example, is used. The composition of this solution is as follows. Nacl 8.00 Na 2 HPO 4 1.15 Kcl 0.20 KH 2 PO 4 0.20 (g/l) Next, a supernatant is obtained from the homogenate by centrifugation or the like. When using centrifugation, it is usually 8000 ~
The test is carried out at 12,000×g for several minutes or more. The obtained supernatant is heated, and denatured high molecular weight proteins are precipitated and removed. Heating is performed at about 60 to 100°C for 1 minute or more. The supernatant is then dialyzed against the above saline solution to remove low molecular weight components. Next, the obtained fraction (or the centrifuged fraction without heating and/or dialysis) is subjected to "Sephadex" G-75, 100 or
200, etc., and the fraction having the first peak of the three peaks obtained is fractionated. Then, when ion exchange chromatography is performed using DEAE cellulose, it is fractionated into 6 to 7 fractions. The second fraction is the growth factor of interest. (Actions and Effects of the Invention) The growth factor of the present invention has the following properties. a ConA (concanavalin A) - eluted by sepharose chromatography. That is, it does not exhibit properties of polysaccharides or glycoproteins. b The electropherogram obtained by SDS polyacrylamide gel has one band at a molecular weight of approximately 20,000. c Does not show species specificity depending on the animal. d It has good thermal stability. e Bovine-derived fetal serum, which has the effect of promoting the proliferation of hepatocytes and is also useful in culturing other tissue cells.
Shows the same culture effect as quasi-fetal serum or calf serum. (Effects of the Invention) As described above, the hepatocyte growth factor according to the present invention is expected to be used as a liver function promoter, etc., and is also useful as a culture promoter in a serum-free medium. (Examples) Hereinafter, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited to the following Examples unless the gist thereof is exceeded. Example 1 (Experiment 1) Fractionation of heated and dialyzed rat small intestine mucosal extract by gel filtration method 1 Experimental animals and rearing conditions Sprague was used for gel filtration.
Dawle type (hereinafter referred to as "SD type") 2-3 years old
Samples obtained from males aged 1 month and weighing 200 to 300 g were used. Rats have free access to both feed and drinking water, with solid feed (Japan Compound Feed KK
(manufactured by J.D.) and reared in an environment kept at around 23°C. 2. Preparation of small intestine mucosal extract Rats were lightly anesthetized with ether, the jugular vein was cut, blood was exsanguinated, the entire small intestine was removed after laparotomy, and the contents were removed.
- Wash with PBS solution (Dulbecco's phosphate buffered saline solution), scrape and collect the mucous membrane with forceps, and homogenize with approximately twice the volume of CMF-PBS solution.
The supernatant obtained by centrifugation at 12,000×g for 30 minutes was used as a small intestinal mucosal extract. 3 Heating and dialysis of small intestine mucosal extract After heating the above-mentioned small intestine mucosal extract at 100°C for 2 minutes,
The mixture was centrifuged at 12,000×g for 20 minutes, and the supernatant was dialyzed against approximately 30 times the volume of CMF-PBS solution for 24 hours. 4. Fractionation by gel filtration method The heated and dialyzed small intestine mucosal extract was concentrated to about 5 ml using a collodion bag, and used as a sample for fractionation. The gel used for gel filtration was
Sephadex G-75 (manufactured by Pharmacia Fine Chemicals) was used. The column had an inner diameter of 1.2 cm and a gel height of 120 cm.
0.1M Nacl・20mM Tris-HCl buffer (PH7.5)
The gel was washed with water, about 2 ml of the sample was added, and the sample was eluted with the same buffer in a descending manner at a flow rate of 2 ml/hr. 2 ml of the eluted buffer was collected using a fraction collector, and the absorbance at 280 nm was measured to obtain an elution curve (Figure 1). As a result, three fractions were obtained, which were used as samples for the next experiment-2. (Experiment 2) Search for hepatocyte proliferation activating factor by culture of mature rat hepatocytes 1 Animals used for culture were 8 weeks old and weighed approximately 150 g.
SD male rats were used and were reared under the same conditions as in Experiment-1. Please note that all hepatocyte isolation and culture operations are performed under sterile conditions.
Particular attention was paid to sterilization. 2 Adult rat hepatocyte isolation method All hepatocytes were isolated by the following method. Rats are anesthetized by intraperitoneal injection of 0.2 ml of Nembutal. Next, the abdomen is shaved, and the entire body is disinfected with a 10% benzalkonium chloride solution (afterwards, all liver cell separation procedures, except shaking and centrifugation, are performed in a sterile box and performed aseptically). The rat is fixed in the supine position on a surgical fixing table, and the abdominal skin and abdominal muscles are opened in this order using surgical scissors.
Use absorbent cotton soaked in CMF-PBS solution to scrape the intestines to the surgeon's right side to fully expose the portal vein. Loop the suture over the portal vein and use the tips of ophthalmic scissors to make a cut into the portal vein. A cannula is inserted into the overflowing blood while flowing preperfusion buffer into the perfusion device previously placed in the incision, and quickly ligated with sutures. At the same time, cut the inferior vena cava below the liver and drain the washing fluid. As is
After approximately 200 ml of preperfusion buffer has flowed at a flow rate of 30 ml/hr, the pump is stopped. Change the perfusate to CMF-PBS solution, wash by flushing about 100 ml at the same flow rate, stop the pump, change the perfusate to collagenase solution,
Flow approximately 30ml at the same flow rate. Once the collagenase has penetrated the entire liver, stop the pump, carefully remove the whole liver, and transfer it to a 120 mm glass jar. about 20
Add 1 ml of collagenase solution and cut the liver into 2 mm square pieces by crossing the razor blade with forceps.
Transfer the shredded tissue together with the collagenase solution to a 100 ml triangular solution, seal with a butyl stopper, and shake for 15 minutes in a thermostatic shaker at 37°C at a rate of 100 shakes per minute. After shaking, remove undigested tissue using a cell sieve, and add about 10 ml of CMF-
Wash the undigested tissue with PBS solution and remove all the solution for 30 min.
Collect in a ml centrifuge tube, cap tightly, and centrifuge at 50 x g for 1 minute. Discard the supernatant and add 20 ml of new CMF−
Add PBS solution to wash, pipette gently, stopper tightly, cool the centrifuge tube on ice, centrifuge at 50 x g for 1 minute, and discard the supernatant. Add CMF-PBS solution again and suspend, filter through a small piece of double nylon cloth,
Collect the liquid in a new centrifuge tube, seal it, cool it on ice, and incubate it at 50x.
g. Centrifuge for 1 minute. After discarding the supernatant,
By repeating washing with the CMF-PBS solution twice, non-parenchymal cells, which have a lower specific gravity than hepatic parenchymal cells, are removed, and hepatic parenchymal cells are separated. 3. Preculture and preculture medium Liver cells damaged by enzymes have lost their original liver function, so in order to rejuvenate them,
Preculture was performed. Liver parenchymal cells purified by low-speed centrifugation were placed in William's E medium (WE medium) containing 5% rat serum (complement detoxified by heating at 56°C for 30 minutes) and 10 -6 M dexamethasone. Suspend and sow at a rate of 1.5 ml in a sterilized plastic tray (35 x 10 mm). Penicillin (100 U/ml), streptomycin (100 ug/ml), amphotericin B (0.25 μg/ml), etc. were added to the culture solution. Culture is 5
% CO2-95 % air as the gas phase in a CO2 incubator at 37°C for 24 hours. After 24 hours, many hepatocytes have adhered to the bottom of the shear plate. 4 Culture method After culturing in the preculture medium for 24 hours, the medium was replaced with the desired medium. The medium used was the above-mentioned WE medium as the basic medium, and a medium supplemented with 10% rat serum as a control.
Fraction 1 (0.02 mg protein/ml), fraction 2 (0.02 mg protein/ml), and fraction 3 (0.01 mg protein/ml) obtained in Experiment-1 were used as experimental sections.
mg protein/ml) was added at 10%, respectively. In addition, fraction 1 (tube No. 33 to 52) and fraction 2 (tube No.
No. 60 to 85) and fraction 3 (tube No. 94 to 120), each in an appropriate amount (around 5 ml) in a collodion bag.
The protein concentration was measured using the Lowly method. Medium was replaced every 48 hours. 5.Measurement date and method of cell number Day 0 is the end of preculture, and day 1, day 3,
Cell numbers were measured on the 6th and 9th days. The measurement method is to take out the shear dish, remove the medium, and add a trypsin-EDTA mixture (0.1% trypsin,
The cells were incubated in 0.02% EDTA-CMF-PBS solution at 37°C for 15 minutes and peeled off repeatedly until no cells remained on the shear plate. 500 ml of the cell suspension
The cells were centrifuged at ×g for 15 minutes, and the cells were collected and suspended in a known amount of CMF-PBS solution. After staining with trypan blue, cells with no nuclear staining were counted as viable cells using a hematometer. In addition, three shears were measured for each experimental section, and the average value was taken as the cell number. 6 Experimental Results The hepatocytes obtained by the perfusion method and low-speed centrifugation treatment yielded approximately 80% viable cells, with almost no contamination by blood cells or non-parenchymal cells. When looking at changes in cell number and morphological changes after culture, significant proliferation was observed in the culture medium to which Fraction 1 was added. Fractions 2 and 3 also showed a tendency to proliferate up to the 3rd day, but as the days passed from the 6th to the 9th day, the number of cells decreased, and fraction 3 became uncultureable after the 6th day. Summer. In the control medium supplemented with 10% rat serum, no growth was observed and culturing became impossible on the 6th day. This experiment revealed that fraction 1 contained a factor with hepatocyte proliferation activity, and that proliferation was maintained for at least 9 days. (Note that the temporary proliferation of fractions 2 and 3 is different from fraction 1 to fraction 2.
This was due to a small amount of contamination in 3 and 3. ) (Experiment 3) Fractionation by ion exchange cellulose column chromatography The cellulose ion exchanger used in the column was
DE-52 (DEAE cellulose: Watmann
Wattman) was used. Use a column with an inner diameter of 3 cm and a height of 30 cm, and use a buffer solution as in Experiment 1.
A cellulose ion exchanger was equilibrated and used. Fraction 1 obtained in Experiment 1 above was concentrated to about 5 ml using a collodion bag and used as a sample for fractionation. After adding 5ml of the sample to the column, 0.1M,
The ionic strength was increased stepwise with 0.2M, 0.3M, 0.4M, 0.6M, and 0.8M NaCl, and the adsorbed substances were eluted. In addition, each type of buffer was eluted at a flow rate of 10 ml/hr with a flow rate of 250 ml, and 5 ml of the eluted buffer was collected using a fraction collector and the absorbance at 280 nm was measured. An elution curve was obtained (Figure 2). This yielded 6 fractions, so the next experiment −
Sample No. 4 was used. (Experiment 4) Search for hepatocyte proliferation activating factor by culture of mature rat hepatocytes The same method as in Experiment 2 above was used. The culture method was the same as in Experiment 2. After 24 hours of pre-culture, the experimental plot was divided into fraction 1 (0.02
mg protein/ml; tube No. 10-25), fraction 2 (0.02 mg protein/ml; tube No. 66-73), fraction 3 (0.02 mg protein/ml; tube No. 66-73)
ml; tube No. 130-150), fraction 4 (0.002 mg protein/
ml; tube No. 157-168), fraction 5 (0.002 mg protein/
ml; tube No. 169-187), fraction 6 (0.002 mg protein/
ml; tube No. 196-202) was added to the basal medium at a concentration of 10%, and the cell number was measured on the first and third day. The physical properties of each fraction were determined by measuring the molecular weight and the presence of sugar by PAS staining, and for the fractions with cell proliferation activity, the protein composition was determined by polyacrylamide electrophoresis. Note that the molecular weight was measured by SDS polyacrylamide electrophoresis. (Experimental Results) Table 1 shows the changes in cell number after culture. That is, only the medium supplemented with fraction 2 showed proliferation. In the measurement of molecular weight, it was revealed that no protein staining reaction (Coomassie brilliant blue staining) was observed in fractions 3, 4, 5, and 6 when measured using SDS polyacrylamide. Fractionation by polyacrylamide electrophoresis is
The analysis was performed on fraction 2 in which cell proliferation activity was observed (ie, the target growth factor). Result 3
Two bands (molecular weight approximately 20,000) were detected by amido black staining. 【table】

【図面の簡単な説明】[Brief explanation of drawings]

図−1はラツト小腸粘膜抽出物のゲルろ過法に
よる溶出曲線を示す図であり、図−2は、図−1
における画分1のイオン交換セルロースクロマト
グラフイーによる溶出曲線を示す図である。
Figure 1 shows the elution curve of rat small intestine mucosal extract by gel filtration method, and Figure 2 shows the elution curve of rat small intestine mucosal extract by gel filtration method.
FIG. 2 is a diagram showing an elution curve of Fraction 1 in ion exchange cellulose chromatography.

Claims (1)

【特許請求の範囲】[Claims] 1 温血動物の腸粘膜のホモジネートより分画さ
れ、分子量が約2万である肝細胞増殖因子。
1. Hepatocyte growth factor that is fractionated from homogenate of intestinal mucosa of warm-blooded animals and has a molecular weight of approximately 20,000.
JP59098978A 1984-05-17 1984-05-17 Hepatic cell proliferation factor Granted JPS60243019A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59098978A JPS60243019A (en) 1984-05-17 1984-05-17 Hepatic cell proliferation factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59098978A JPS60243019A (en) 1984-05-17 1984-05-17 Hepatic cell proliferation factor

Publications (2)

Publication Number Publication Date
JPS60243019A JPS60243019A (en) 1985-12-03
JPH0533206B2 true JPH0533206B2 (en) 1993-05-19

Family

ID=14234105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59098978A Granted JPS60243019A (en) 1984-05-17 1984-05-17 Hepatic cell proliferation factor

Country Status (1)

Country Link
JP (1) JPS60243019A (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01143900A (en) * 1987-11-30 1989-06-06 Terumo Corp Hepatic reparative factor
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
WO1993023541A1 (en) * 1992-05-18 1993-11-25 Genentech, Inc. Hepatocyte growth factor variants
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
CN1069650C (en) * 1995-12-29 2001-08-15 中国科学院上海药物研究所 Method for separation and purification of lentinan
US8962813B2 (en) * 2006-01-25 2015-02-24 Octapharma Ag Purification and use of a factor for supporting wound healing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5862116A (en) * 1981-10-09 1983-04-13 Mitsubishi Chem Ind Ltd Multiplication promoting substance for hepatic cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5862116A (en) * 1981-10-09 1983-04-13 Mitsubishi Chem Ind Ltd Multiplication promoting substance for hepatic cell

Also Published As

Publication number Publication date
JPS60243019A (en) 1985-12-03

Similar Documents

Publication Publication Date Title
Jaffe Culture and identification of large vessel endothelial cells
AU621148B2 (en) Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
Cromartie et al. Arthritis in rats after systemic injection of streptococcal cells or cell walls.
Papageorgiou et al. Production and characterization of migration inhibitory factor (s)(MIF) of established lymphoid and non-lymphoid cell lines
CN109090102A (en) A kind of general serum-free frozen stock solution of mescenchymal stem cell and preparation method thereof
CN103702674B (en) Composition, purposes and the preparation of platelet cracking content
US4511653A (en) Process for the industrial preparation of collagenous materials from human placental tissues, human collagenous materials obtained and their application as biomaterials
CN108714155A (en) Blood platelet extract of inactivation of virus and application thereof and preparation
Dubowitz Enzymatic maturation of skeletal muscle
JP2015071610A (en) Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
CN108348555A (en) Methods for cell expansion and therapeutic combination
JPS58500273A (en) tissue culture medium
Codington et al. Further studies on the relationship between large glycoprotein molecules and allotransplantability in the TA3 tumor of the mouse: studies on segregating TA3-HA hybrids
JPH0533206B2 (en)
KR930000188B1 (en) Novel lymphokine monoclonal antibody specific to the lymphokine
SCHWARZ et al. The characterization and partial purification of hepatocyte proliferation factor
Vassar Electrophoretic mobility of human tumour cells
Azizkhan et al. Stimulation of increased capillary endothelial cell motility by chondrosarcoma cell-derived factors
Pizzo et al. Suppression of lymphocyte activation by a protein released from isolated perfused rat liver
Meijer et al. Membrane and transformation characteristics of lymphocytes isolated from the synovial membrane and paired peripheral blood of patients with rheumatoid arthritis
JPH0154991B2 (en)
JPS62116519A (en) Cell metabolism activating substance extracted from placenta, extraction thereof and method for inactivating hepatitis virus
JPS61260022A (en) Liver-like artificial tissue and production thereof
JPS62161730A (en) Production inducer for cell growth factor
JPH0148886B2 (en)

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term